Developing the latest breakthrough drug just doesn’t pay these days as much as creating the hot new web app does.
Private life sciences companies in Silicon Valley that got financing in the fourth quarter of 2011 had an average per-share value that was about 10 percent higher than their previous round of financing, which typically was completed 12-18 months prior, according to an analysis by the law firm Fenwick & West.
To read the full, original article click on this link: Biotech Lagging Behind Go-Go Web Valuations, Survey Says | Xconomy
